Systematic review and meta-analysis: ...
Document type :
Article dans une revue scientifique: Article de synthèse/Review paper
DOI :
PMID :
Permalink :
Title :
Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index
Author(s) :
Lo, B [Auteur]
Prosberg M., V [Auteur]
Gluud L., L [Auteur]
Chan, Wesley [Auteur]
Leong R., W [Auteur]
Van Der List, E [Auteur]
Van Der Have, M [Auteur]
Sarter, Helene [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gower, Corinne [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Peyrin-Biroulet, Laurent [Auteur]
Vind, I [Auteur]
Burisch, Johan [Auteur]
Prosberg M., V [Auteur]
Gluud L., L [Auteur]
Chan, Wesley [Auteur]
Leong R., W [Auteur]
Van Der List, E [Auteur]
Van Der Have, M [Auteur]
Sarter, Helene [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Gower, Corinne [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Peyrin-Biroulet, Laurent [Auteur]
Vind, I [Auteur]
Burisch, Johan [Auteur]
Journal title :
Alimentary Pharmacology and Therapeutics
Abbreviated title :
Aliment. Pharmacol. Ther.
Volume number :
47
Pages :
6-15
Publication date :
2018-01
ISSN :
0269-2813
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background
The Inflammatory Bowel Disease Disability Index (IBD-DI) has recently been developed for patients with Crohn's disease (CD) and ulcerative colitis (UC).
Aim
To assess the severity of disability and associated ...
Show more >Background The Inflammatory Bowel Disease Disability Index (IBD-DI) has recently been developed for patients with Crohn's disease (CD) and ulcerative colitis (UC). Aim To assess the severity of disability and associated factors using the IBD-DI, and review the validity of the IBD-DI as a tool. Method Systematic review of cross-sectional studies. Patients included had UC or CD and were classified as active, in remission, or needing surgery, biological and/or steroid treatment. We included studies assessing disability using the IBD-DI and that were captured by electronic and manual searches (January 2017). The possibility of bias was evaluated with the Newcastle-Ottawa Scale. Results Nine studies were included with 3167 patients. Comparatively, patients with active disease had higher disability rates than those in remission (SMD [CI95] = 1.49[1.11, 1.88], I2 = 94%, P<.01), while patients on biological treatment had lower disability rates than those receiving corticosteroid treatment (SMD [CI95] = −0.22[−0.36, −0.08], I2 = 0%, P<.01). Disease activity and unemployment were found to be associated factors. The IBD-DI scored “good” for internal consistency, “fair” to “excellent” for intra-rater reliability and “excellent” for inter-rater reliability. Construct validity was “moderately strong” to “very strong” and structural validity was found to be mainly unidimensional. The IBD-DI had excellent responsiveness, while its interpretability was only useful on a group level. Conclusions This systematic review and meta-analysis found a significant association between disease activity, treatment received and disability; although significant heterogeneity was found. The IBD-DI is reliable and valid, but further studies are needed to measure its interpretability.Show less >
Show more >Background The Inflammatory Bowel Disease Disability Index (IBD-DI) has recently been developed for patients with Crohn's disease (CD) and ulcerative colitis (UC). Aim To assess the severity of disability and associated factors using the IBD-DI, and review the validity of the IBD-DI as a tool. Method Systematic review of cross-sectional studies. Patients included had UC or CD and were classified as active, in remission, or needing surgery, biological and/or steroid treatment. We included studies assessing disability using the IBD-DI and that were captured by electronic and manual searches (January 2017). The possibility of bias was evaluated with the Newcastle-Ottawa Scale. Results Nine studies were included with 3167 patients. Comparatively, patients with active disease had higher disability rates than those in remission (SMD [CI95] = 1.49[1.11, 1.88], I2 = 94%, P<.01), while patients on biological treatment had lower disability rates than those receiving corticosteroid treatment (SMD [CI95] = −0.22[−0.36, −0.08], I2 = 0%, P<.01). Disease activity and unemployment were found to be associated factors. The IBD-DI scored “good” for internal consistency, “fair” to “excellent” for intra-rater reliability and “excellent” for inter-rater reliability. Construct validity was “moderately strong” to “very strong” and structural validity was found to be mainly unidimensional. The IBD-DI had excellent responsiveness, while its interpretability was only useful on a group level. Conclusions This systematic review and meta-analysis found a significant association between disease activity, treatment received and disability; although significant heterogeneity was found. The IBD-DI is reliable and valid, but further studies are needed to measure its interpretability.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Research team(s) :
IBD and environnemental factors : epidemiology and functional analyses
Submission date :
2019-03-01T14:26:43Z
2024-02-12T10:23:25Z
2024-02-12T10:23:25Z